Distinguished in Virilizing Ovarian Tumor

Dr. Pallavi P. Kumar

Hematology Oncology | Oncology | Hematology
Sinai Hospital Of Baltimore, Inc
5401 Old Court Rd, 
Randallstown, MD 
 (2319.7 mi)
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Distinguished in Virilizing Ovarian Tumor
Sinai Hospital Of Baltimore, Inc
5401 Old Court Rd, 
Randallstown, MD 
 (2319.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

Pallavi Kumar is a Hematologist Oncology specialist and an Oncologist in Randallstown, Maryland. Dr. Kumar and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Familial Pancreatic Cancer. Dr. Kumar is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
Northwest Hospital Center
Carroll Hospital Center
Sinai Hospital Of Baltimore
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare
  •  Humana

Locations

SINAI HOSPITAL OF BALTIMORE, INC
5401 Old Court Rd, Randallstown, MD 21133

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Other
Study Phase: Phase 3
Targeted Intra-arterial Gemcitabine Vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Targeted Intra-arterial Gemcitabine Vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: December 09, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Recruiting
Publish Date: April 18, 2024
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2023
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer
A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Other
A Pilot Randomized Control Trial of Advance Care Planning and Triggered Palliative Care for Cancer Patients Undergoing Stem Cell Transplantation (RCT of ACP for Transplant)
A Pilot Randomized Control Trial of Advance Care Planning and Triggered Palliative Care for Cancer Patients Undergoing Stem Cell Transplantation (RCT of ACP for Transplant)
Enrollment Status: Withdrawn
Publish Date: September 20, 2018
Intervention Type: Other
View 9 Less Clinical Trials

2 Total Publications

NCCN Guidelines® Insights: Distress Management, Version 2.2023.
NCCN Guidelines® Insights: Distress Management, Version 2.2023.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 08, 2023
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Frederick D. Min
Hematology Oncology | Hematology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Frederick D. Min
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

7350 Van Dusen Rd, Suite 370, 
Laurel, MD 
 (19.4 mi)
301-982-9800
Languages Spoken:
English, Korean
Accepting New Patients
Offers Telehealth

Frederick Min is a Hematologist Oncology specialist and a Hematologist in Laurel, Maryland. Dr. Min and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Pleuropulmonary Blastoma, and Ovarian Cancer. Dr. Min is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Panayotis Ledakis
Hematology Oncology | Oncology | Hematology
Distinguished in Virilizing Ovarian Tumor
Dr. Panayotis Ledakis
Hematology Oncology | Oncology | Hematology

Lutherville Hematology And Oncology Services

7602 Belair Rd, 
Baltimore, MD 
 (14.0 mi)
410-494-9099
Languages Spoken:
English, French, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Panayotis Ledakis is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Ledakis and is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy. Dr. Ledakis is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Jeanine L. Werner
Hematology Oncology | Hematology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Jeanine L. Werner
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

10710 Charter Dr, Suite G020, 
Columbia, MD 
 (11.4 mi)
410-964-2218
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanine Werner is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Werner and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Breast Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Ovarian Carcinosarcoma. Dr. Werner is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile